Zsírmáj (MASLD/MASH): vizsgálatok itt: Lengyelország
13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év to 80 év
- People
- 1650 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06215716 - 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Cracow, Lodz, Lublin, Myslowice, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Cracow, Lodz, Lublin, Myslowice, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 3. fázisTaking peopleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Where
- Cracow, Czestochowa, Gdansk, Katowice, Lodz, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 205 worldwide
- Run by
- Akero Therapeutics Inc.
See details and how to join2024-512895-36-00 · EU 2024-512895-36-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Cracow, Lodz, Myslowice, Warsaw, Wroclaw
- Életkor
- 18 év to 80 év
- People
- 1350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Cracow, Lodz, Myslowice, Warsaw, Wroclaw
- Életkor
- 18 év to 75 év
- People
- 1800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - 3. fázisNot yet taking people in LengyelországA pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
- Where
- Cracow, Myslowice, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 382 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00 - 3. fázisNot yet taking people in LengyelországA study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
- Where
- Cracow, Myslowice, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 69 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00 - 3. fázisTaking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Częstochowa, Gdansk, Katowice, Krakow, Lodz, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év to 80 év
- People
- 2150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Bialystok, Gdansk, Katowice, Lodz, Mysłowice, Poznan, Rzeszów, Warsaw, Zamość
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Cracow, Katowice, Lodz, Lublin, Myslowice, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év to 75 év
- People
- 1250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - 3. fázisTaking peopleA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Cracow, Czestochowa, Gdansk, Gdynia, Katowice, Lodz, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 244 worldwide
- Run by
- Akero Therapeutics Inc.
See details and how to join2023-505141-48-00 · EU 2023-505141-48-00 - No phaseNot yet taking people in LengyelországENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study
- Where
- Wroclaw
- Életkor
- 18 év to 75 év
- People
- 10 000
- Run by
- Jarosław Drobnik
See details and how to joinNCT07336563